Valerie Odegard - Concepedia

Author

Valerie Odegard

Neoleukin Therapeutics (United States)

Also Known As

V. Odegard, V.H. Odegard, Valerie H Odegard, Valerie H. Odegard, Valerie Odegard

Publications

755

Citations

H-Index

Concepts

All Affiliations

Neoleukin Therapeutics (United States)Howard Hughes Medical Institute Yale University Massachusetts General Hospital The University of Texas MD Anderson Cancer Center

About

Valerie Odegard is an author at Neoleukin Therapeutics (United States) specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	291
2	Cell Biology	4	4	188
3	Natural Sciences	2	2	168
4	Allergy	1	1	54
5	Cellular Physiology	1	1	54

Valerie Odegard

Publications

337

Citations

H-Index

Page 1

	Year	Citations
Expression of activation-induced cytidine deaminase is regulated by cell division, providing a mechanistic basis for division-linked class switch recombination James S. Rush, Man Liu, Valerie Odegard, Proceedings of the National Academy of Sciences Molecular RegulationMechanistic BasisImmunologyMolecular BiologyCell Cycle	2005	91
Histone Modifications Associated with Somatic Hypermutation Valerie Odegard, Sean Kim, Shannon M. Anderson, Immunity Histone ModificationsChromatinSomatic HypermutationChromatin RemodelingNatural Sciences	2005	77
Antibody-Mediated Targeting of the Orai1 Calcium Channel Inhibits T Cell Function Jennifer H. Cox, Scott Hussell, Henrik Søndergaard, PLoS ONE T-regulatory CellImmunologyImmunologic MechanismAntigen ProcessingImmunotherapy	2013	54
Roles of the Ig κ Light Chain Intronic and 3′ Enhancers in <i>Igk</i> Somatic Hypermutation Matthew A. Inlay, Heather H. Gao, Valerie Odegard, The Journal of Immunology	2006	46
SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist. Heather Metz, Monica Childs, Jamie Brevik, Journal of Clinical Oncology Sbt6050 BindImmunologyBiological TherapyInnate ImmunityHer2-directed Tlr8 Therapeutic	2020	30
209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors Samuel J. Klempner, M. Beeram, Dhanusha Sabanathan, Annals of Oncology Sbt6050 MonotherapyMedicineImmunologyPathologyImmune Checkpoint Inhibitor	2021	26
317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors Leisha A. Emens, Muralidhar Beeram, Erika Hamilton, Regular and Young Investigator Award Abstracts ImmunologyImmunoeditingNk CellsImmunologic MechanismInnate Immunity	2020	13

Page 1